Physiologically‐based pharmacokinetic model‐based translation of <scp>OATP1B</scp> ‐mediated drug–drug interactions from coproporphyrin I to probe drugs-Reference-Cited by-同舟云学术

Physiologically‐based pharmacokinetic model‐based translation of OATP1B ‐mediated drug–drug interactions from coproporphyrin I to probe drugs

Published:2022-05-02 Issue:6 Volume:15 Page:1519-1531
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Mochizuki Tatsuki¹,Aoki Yasunori²,Yoshikado Takashi³,Yoshida Kenta⁴^ORCID,Lai Yurong⁵^ORCID,Hirabayashi Hideki⁶,Yamaura Yoshiyuki⁷,Rockich Kevin⁸,Taskar Kunal⁹,Takashima Tadayuki¹⁰,Chu Xiaoyan¹¹,Zamek‐Gliszczynski Maciej J.¹²,Mao Jialin¹³,Maeda Kazuya¹^ORCID,Furihata Kenichi¹⁴,Sugiyama Yuichi¹²,Kusuhara Hiroyuki¹

Affiliation:

1. Laboratory of Molecular Pharmacokinetics Graduate School of Pharmaceutical Sciences, The University of Tokyo Tokyo Japan

2. Laboratory of Quantitative System Pharmacokinetics/Pharmacodynamics School of Pharmacy Josai International University Tokyo Japan

3. Laboratory of Clinical Pharmacology Yokohama University of Pharmacy Yokohama Kanagawa Japan

4. Clinical Pharmacology Genentech, Inc. South San Francisco California USA

5. Drug Metabolism Gilead Sciences Inc. Foster City California USA

6. Drug Metabolism and Pharmacokinetics Research Laboratories, Research Takeda Pharmaceutical Company Limited Kanagawa Japan

7. Pharmacokinetic Research Laboratories Ono Pharmaceutical Co., Ltd. Osaka Japan

8. Drug Metabolism, Pharmacokinetics, and Clinical Pharmacology Incyte Research Institute Wilmington Delaware USA

9. Drug Metabolism and Pharmacokinetics IVIVT, GlaxoSmithKline Stevenage UK

10. Laboratory for Safety Assessment & ADME, Pharmaceuticals Research Center Asahi Kasei Pharma Corporation Shizuoka Japan

11. Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism Merck & Co., Inc. Kenilworth New Jersey USA

12. Drug Metabolism and Disposition GlaxoSmithKline Collegeville Pennsylvania USA

13. Drug Metabolism and Pharmacokinetics Genentech, Inc. South San Francisco California USA

14. P‐One Clinic Keikokai Medical Corp Tokyo Japan

Funder

Genentech Foundation

Gilead Sciences

GlaxoSmithKline

Merck

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13272

Reference35 articles.

1. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans

2. Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations

3. Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

4. Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

5. Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis on dynamic changes of etizolam and its metabolites and exploration of its development prospect using UPLC-Q-exactive-MS;Journal of Pharmaceutical and Biomedical Analysis;2024-03

2. Cluster Gauss‐Newton method for a quick approximation of profile likelihood: With application to physiologically‐based pharmacokinetic models;CPT: Pharmacometrics & Systems Pharmacology;2023-10-18

3. Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry;Clinical Pharmacology & Therapeutics;2023-10-11

4. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor;Journal of Pharmaceutical Sciences;2023-09

5. A 20-Year Research Overview: Quantitative Prediction of Hepatic Clearance Using the In Vitro-In Vivo Extrapolation Approach Based on Physiologically Based Pharmacokinetic Modeling and Extended Clearance Concept;Drug Metabolism and Disposition;2023-07-05